Piramal Pharma Share Price

Piramal Pharma Share Price

NSE: PPLPHARMA
|
Pharmaceuticals

₹ 196.01

-₹0.65 (-0.33%)
1D
Last updated 13 Oct, 2026, 15:50 IST

Piramal Pharma Share Price Today

As of 14 Oct 2026, Piramal Pharma share price is ₹196.01. The stock opened at ₹196.40, compared to its previous close of ₹196.66. During today's trading session, Piramal Pharma share price moved in the range of ₹191.41 to ₹197.00, with an average price of ₹194.20 for the day. Looking at its last 52-week, the stock has touched a low of ₹132.30 and a high of ₹231.93. On the performance front, Piramal Pharma share price has increased by 33.82% over the last six months and is down 0.79% on a year-on-year basis.

₹191.41
0.33% down today
₹197.00
1D LOW
1D HIGH

Piramal Pharma Returns Calculator

Volume
13,90,936
Average traded price
₹194.20
Last traded time
03:50:58 13 Oct
Last traded quantity
8
Circuit
L
H
₹157.33
₹235.99
52-week
L
H
₹132.30
₹231.93
Mkt Cap Cr
26,154.33
P/E
-83.24
P/B
3.2
ROA
-1.75%
ROE
-3.58%
ROCE
2.58%
Quick Ratio
0.87
EV/EBITDA
27.98
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Piramal Pharma has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Piramal Pharma appears overvalued compared to its peers
Step 1 of 5
Earnings
Very Poor
Piramal Pharma revenue, operating profits and net profits have been degrowing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,067.0134.835.0511.19%13.74%17.33%2.3121.42
Divis Laboratories2,48,982.9885.1214.8514.6%15.32%19.56%3.556.28
Torrent Pharmaceuticals1,76,300.5082.5521.164.87%25.49%13.85%0.7538.11
Zydus Lifesciences1,13,615.6924.744.198.57%18.59%17.35%0.9114.87
Laurus Labs1,11,898.66102.6321.1110.38%16.77%16.14%0.6853.86
Cipla1,06,129.9631.623.087.92%11.27%14.95%2.517.83
Dr. Reddy's Laboratories1,02,707.4132.262.75.48%11.07%12.54%1.3515.86
Mankind Pharma99,089.5247.926.087.36%11.74%13.13%0.7425.7
Aurobindo Pharma97,972.4726.42.596.34%9.25%11.76%1.1512.47
Lupin89,628.8316.033.9614.47%23.76%24.88%1.429.56

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About Piramal Pharma

Piramal Pharma Share Price
ISIN
INE0DK501011
Sector Market Cap
₹ 26,154.33 Cr

Piramal Pharma Limited is a pharmaceutical company offering a portfolio of differentiated products and services through its global distribution network. Part of Piramal Group, the company has 17 global facilities with a network expanding in more than 100 countries. Piramal Group's presence in the pharma business goes back to 1988. It entered the space with the acquisition of Nicholas Laboratories in 1988. Over the years it transformed into the Piramal Healthcare network. In 2010, the pharma arm of Piramal Group sold the domestic formulations business to Abbott and diagnostic services to Super Religare Laboratories. Piramal Pharma then became part of Piramal Enterprises Limited.

Business operations

Piramal Pharma Solutions (PPS) and Piramal Critical Care (PCC) are subsidiaries of the company. PPS is the contractor development and manufacturing organisation (CDMO) under PPL, looking after end-to-end development and manufacturing solutions across the drug lifecycle.

Piramal Critical Care’s complex hospital product portfolio offers anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and other critical therapies. Its manufacturing facilities in the US and India have cleared periodic inspections by the US FDA, UK MHRA and other regulators.

The company sells its over-the-counter products like Lacto Calamine, I-Pill, Polycrol and Tetmosol through India Consumer Healthcare (ICH).

Piramal Pharma Limited was incorporated as a public firm in 2020. The company acquired the pharmaceutical business from Piramal Enterprises Limited. It received a growth equity investment from Carlyle Group Limited in the same year.

Piramal Pharma acquired a 100% stake in Convergence Chemicals Private Limited (CCPL). It also announced an expansion for antibody-drug conjugates at its Grangemouth (UK) facility and the drug substance capabilities at its Riverview facility (USA). The next year, the company acquired Hemmo Pharmaceuticals Private Limited (HPPL). The pharmaceutical business of Piramal Enterprises Limited (PEL) was demerged to PPL. The company's wholly-owned subsidiaries CCPL and HPPL were amalgamated into the firm.

Piramal Pharma has a joint venture, Allergan India Private Limited, with Allergan(now AbbVie), a key player in ophthalmology in the Indian market. It holds 49% of the paid-up capital in this venture. The company also has a minority stake of 33.33% in Yapan Bio, a company operating in the biologics/ bio-therapeutics and vaccine segments.

Piramal Pharma was listed on the Indian stock market in 2022. In FY 2023, the company launched its e-commerce website weelify.in to consolidate its presence in the e-commerce space.

Piramal Pharma’s market capitalisation stood at nearly ₹18,800 crore as of January 12, 2024. Piramal Pharma share price has moved up by 22.4% in the last one year.

Piramal Pharma Financial Highlights

  • Revenue: Piramal Pharma reported revenue of ₹9,082.38 crore in FY26 vs ₹9,285.99 crore in FY25. It showed a decrease of 2.19% on a yearly basis.
  • Operating Profit: Piramal Pharma reported an operating loss of ₹176.06 crore in FY26 vs ₹414.64 crore in FY25. It showed a decrease of 142.46% on a year-on-year basis.
  • Net Profit: Piramal Pharma reported a net loss of ₹325.94 crore in FY26 vs ₹91.13 crore in FY25. It showed a decrease of 457.66% on a yearly basis.

Piramal Pharma Quarterly Result Highlights

  • Piramal Pharma reported revenue of ₹2,359.33 crore in Jun 2026, compared with ₹2,797.83 crore in Mar 2026, representing a decrease of 15.67% on a quarter-on-quarter (QoQ) basis.
  • Piramal Pharma reported an operating loss of ₹7.46 crore in Jun 2026, compared with ₹43.00 crore in Mar 2026, representing a decrease of 117.35% on a quarter-on-quarter (QoQ) basis.
  • Piramal Pharma reported a loss of ₹69.39 crore in Jun 2026, compared with ₹8.83 crore in Mar 2026, reflecting a decrease of 685.84% on a QoQ basis.
  • The earnings per share (EPS) of Piramal Pharma stood at ₹2.46 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
34.80%
FII
12.52%
Other DII
1.39%
Retail and other
38.11%
Mutual funds
13.18%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 202530.27%
Dec 202529.66%
Mar 202630.18%
Jun 202612.52%
1 day
-0.33%
1 week
-2.25%
1 month
-7.26%
1 year
-0.79%
3 years
+101.86%
5 years
+3.16%
Day
Open / Close
Change %
13 Oct 26
₹196.40 / ₹196.01
-0.33%
12 Oct 26
₹197.29 / ₹196.66
-0.11%
09 Oct 26
₹197.00 / ₹196.88
+0.23%
08 Oct 26
₹203.50 / ₹196.43
-3.24%
Show more

Piramal Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹8,869.08₹9,151.18₹8,171.16₹7,081.55
Other Income₹213.30₹134.81₹175.39₹225.11
Total Revenue₹9,082.38₹9,285.99₹8,346.55₹7,306.66
Total Expenses₹9,119.50₹8,944.28₹8,163.96₹7,474.18
Profit Before Tax-₹176.06₹414.64₹179.29-₹120.15
Tax₹149.88₹323.51₹161.47₹66.31
Profit After Tax-₹325.94₹91.13₹17.82-₹186.46
EPS - Basic-₹2.46₹0.69₹0.14-₹1.54
EPS - Diluted-₹2.46₹0.68₹0.14-₹1.54

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹233.26₹341.71₹119.80-₹160.56
Income before WC changes₹1,336.19₹1,714.37₹1,395.68₹974.97
Change in Assets-₹602.79-₹500.54-₹880.44-₹53.24
Change in Liabilities₹1,129.35₹12.83₹646.14-₹248.84
Change in WC₹526.56-₹487.71-₹234.30-₹302.08
Cash flow from Operations₹1,652.60₹892.30₹1,004.54₹483.89
Cash flow from Investing-₹826.03-₹477.46-₹434.01-₹1,338.78
Cash flow from Financing-₹38.98-₹440.83-₹422.36₹817.79
Total Cash Flow₹787.59-₹25.99₹148.17-₹37.10
Cash (Start of the year)₹182.32₹219.19₹53.23₹85.18
Cash (End of the year)₹976.26₹182.32₹219.19₹53.23

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹10,773.38₹9,880.60₹9,847.34₹9,687.08
Current Assets₹7,191.66₹5,796.99₹5,464.47₹4,835.48
Total Assets₹17,965.04₹15,677.59₹15,311.81₹14,522.56
Current Liabilities₹4,758.28₹3,766.27₹4,369.30₹3,843.05
Net Current Asset₹2,433.38₹2,030.72₹1,095.17₹992.43
Non-Current Liabilities₹5,044.14₹3,785.85₹3,031.14₹3,906.01
Equity Capital₹8,162.62₹8,125.47₹7,911.37₹6,773.50
Total Equity & Liabilities₹17,965.04₹15,677.59₹15,311.81₹14,522.56

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹4,782.01₹5,285.71₹4,390.11₹3,443.22
Other Income₹662.73₹207.35₹202.06₹341.07
Total Revenue₹5,444.74₹5,493.06₹4,592.17₹3,784.29
Total Expenses₹4,475.46₹4,581.92₹4,084.55₹3,653.64
Profit Before Tax₹876.77₹911.14₹507.62₹123.69
Tax₹176.76₹219.74₹116.40₹54.19
Profit After Tax₹700.01₹691.40₹391.22₹69.50
EPS - Basic₹5.28₹5.22₹3.05₹0.57
EPS - Diluted₹5.25₹5.20₹3.05₹0.57

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹876.77₹911.14₹507.62₹123.69
Income before WC changes₹728.21₹1,175.65₹728.88₹174.39
Change in Assets-₹301.64-₹420.51-₹820.37₹266.75
Change in Liabilities₹1,020.32₹27.92₹527.59-₹309.59
Change in WC₹718.68-₹392.59-₹292.78-₹42.84
Cash flow from Operations₹1,328.12₹548.77₹358.29₹71.52
Cash flow from Investing-₹317.83-₹549.98-₹635.52-₹435.05
Cash flow from Financing-₹615.13-₹61.74₹451.38₹290.12
Total Cash Flow₹395.16-₹62.95₹174.15-₹73.41
Cash (Start of the year)₹163.87₹228.80₹54.28₹127.69
Cash (End of the year)₹559.03₹163.87₹228.80₹54.28

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹7,355.17₹6,855.95₹6,259.33₹5,693.72
Current Assets₹4,398.10₹3,535.88₹3,291.55₹2,348.68
Total Assets₹11,753.27₹10,391.83₹9,550.88₹8,042.40
Current Liabilities₹2,766.28₹2,306.49₹2,227.82₹1,951.29
Net Current Asset₹1,631.82₹1,229.39₹1,063.73₹397.39
Non-Current Liabilities₹845.86₹632.80₹610.99₹829.32
Equity Capital₹8,141.13₹7,452.54₹6,712.07₹5,261.79
Total Equity & Liabilities₹11,753.27₹10,391.83₹9,550.88₹8,042.40
* All values are in INR Crore
Qty
Bid
2753
196.01
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 2753
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
2
Neutral
4
Bullish
2
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
41.08
Neutral
ATR (14)
6.57
Neutral
STOCH(9,6)
15.9
Bullish
STOCH RSI (14)
28.82
Neutral
ADX(9)
28.74
Bearish
UO(9)
36.28
Neutral
ROC(12)
-6.68
Bearish
WillR(14)
-86.9
Bullish
Period
Simple value
Exponential vaue
5D
198.7
198.18
10D
200.85
200.57
20D
204.63
203.75
50D
208.75
202.65
100D
190.87
193.39
Volume trend — traded volume by day
13 Oct13L
12 Oct14L
9 Oct13L
8 Oct18L
7 Oct22L
Average16L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Piramal Pharma Share Price
Piramal Pharma
Pharmaceuticals
Add Stock
Add Another

Piramal Pharma Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.